Inhaled versus systemic antibiotics and airway inflammation in children with cystic fibrosis and Pseudomonas

Pediatric Pulmonology

Volumn 45, Issue 3, 2010, Pages 281-290

  Noah, Terry L ^a   Ivins, Sally S ^a   Abode, Kathleen A ^a   Stewart, Paul W ^b   Michelson, Peter H ^c   Harris, William T ^d   Henry, Marianna M ^a   Leigh, Margaret W ^a  

^a UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^b IL   (United States)

^c DUKE UNIVERSITY MEDICAL CENTER   (United States)

^d University of Alabama at Birmingham   (United States)

Author keywords

Bronchoalveolar lavage fluid; Cystic fibrosis; Cytokine; Neutrophil

Indexed keywords

CEFTAZIDIME; CIPROFLOXACIN; TOBRAMYCIN;

ADOLESCENT; ANTIBIOTIC THERAPY; ARTICLE; CHILD; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYSTIC FIBROSIS; DISEASE COURSE; DISEASE SEVERITY; DRUG EFFICACY; FEMALE; HUMAN; LUNG LAVAGE; MALE; NEUTROPHIL; NONHUMAN; PRIORITY JOURNAL; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTION; RANDOMIZED CONTROLLED TRIAL; RESPIRATORY TRACT INFLAMMATION; SYSTEMIC THERAPY; TREATMENT OUTCOME;

ADMINISTRATION, INHALATION; ANTI-BACTERIAL AGENTS; BRONCHOALVEOLAR LAVAGE FLUID; CHILD; CHILD, PRESCHOOL; CYSTIC FIBROSIS; FEMALE; HUMANS; INFANT; INFUSIONS, INTRAVENOUS; MALE; PNEUMONIA, BACTERIAL; PSEUDOMONAS INFECTIONS;

EID: 77449097917     PISSN: 87556863     EISSN: 10990496     Source Type: Journal    
DOI: 10.1002/ppul.21176     Document Type: Article

References (27)

1. Hoiby N, Frederiksen B, Pressler T. Eradication of early Pseudomonas aeruginosa infection. J Cystic Fibrosis 2005;4: 49-54.
2. Doring G, Hoiby N. Early intervention and prevention of lung disease in cystic fibrosis: a European consensus. J Cystic Fibrosis 2004;3:67-91.
3. Lahiri T. Approaches to the treatment of initial Pseudomonas aeruginosa infection in children who have cystic fibrosis. Clin Chest Med 2007;28:307-318.
4. Wood DM, Smyth AR. Antibiotic strategies for eradicating Pseudomonas aeruginosa in people with cystic fibrosis. Cochrane Database Syst Rev 2006; Art. No.:CD004197. 10.1002/ 14651858.CD004197.pub2.
5. Remmington T, Jahnke N, Harkensee C. Oral anti-pseudomonal antibiotics for cystic fibrosis. Cochrane Database Syst Rev 2007; Art. No.:CD005405. 10.1002/14651858.CD005405.pub2.
6. Elizur A, Cannon CI, Ferkol TW. Airway inflammation in cystic fibrosis. Chest 2008;133:489-495.
7. Voynow JA, Fischer BM, Zheng S. Proteases and cystic fibrosis. Intl J Biochem Cell Biol 2008;40:1238-1245.
8. Muhlebach MS, Stewart P, Leigh MW, Noah TL. Quantitative relationship between bacterial infection and inflammation in bronchoalveolar lavage fluids from children with cystic fibrosis. Am J Resp Crit Care Med 1999;160:186-191.
9. Armstrong DS, Hook SM, Jamsen KM, Nixon GM, Carzino R, Carlin JB, Robertson CF, Grimwood K. Lower airway inflammation in infants with cystic fibrosis detected by newborn screening. Pediatr Pulmonol 2005;40:500-510.
10. Konstan M. Therapies aimed at airway inflammation in cystic fibrosis. Clin Chest Med 1998;19:505-513.
11. Gibson RL, Emerson J, McNamara S, Burns LL, Rosenfeld M, Yunker A, Hamblett N, Accurso F, Dovcy M, Hiatt P, et al., and the Cystic Fibrosis Therapeutics Development Network Study Group. Significant microbiological effect of inhaled tobramycin in young children with cystic fibrosis. Am J Resp Crit Care Med 2003;167:841-849.
12. Husson MO, Wizla-Derambure N, Turck D, Gosset P, Wallaert B. Effect of intermittent inhaled tobramycin on sputum cytokine pro-files in cystic fibrosis. J Antimicrob Chemo 2005;56:247-249.
13. Gibson RL, Emerson J, Mayer-Hamblett N, Burns JL, McNamara S, Accurso FJ, Konstan MW, Chatfield BA, Retsch-Bogart G, Waltz DA, Acton J, Zeitlin P, Hiatt P, Moss R,Williams J, Ramsey BW. Duration of treatment effect after tobramycin solution for inhalation in young children with cystic fibrosis. Pediatr Pulmonol 2007;42:610-623.
14. Moriarty TF, McElnay JC, Elborn JS, Tunney MM. Sputum antibiotic concentrations: implications for treatment of cystic fibrosis lung infection. Pediatr Pulmonol 2007;42:1008-1017.
15. Rosenfeld M, Emerson J, Williams-Warren J, Pepe M, Smith A, Montgomery AB, Ramsey B. Defining a pulmonary exacerbation in cystic fibrosis. J Pediatr 2001;139:359-365.
16. Ordonez CL, Henig NR, Mayer-Hamblett N, Accurso FJ, Burns JL, Chmiel JF, Daines CL, Gibson RL, McNamara S, Retsch-Bogart GZ, Zeitlin PL, Aitken ML. Inflammatory and microbiologic markers in induced sputum after intravenous antibiotics in cystic fibrosis.Am J Resp Crit Care Med 2003;168:1471-1475.
17. Smith AL, Redding G, Doershuk C, Goldmann D, Gore E, Hilman B, Marks M, Moss R, Ramsey B, Rubio T, et al. Sputum changes associated with therapy for endobronchial exacerbation in cystic fibrosis. J Pediatr 1988;112:547-554.
18. West SE, Zeng L, Lee BL, Korosok MR, Laxova A, Rock MJ, Splaingard MJ, Farrell PM. Respiratory infections with Pseudomonas aeruginosa in children with cystic fibrosis: early detection by serology and assessment of risk factors. JAMA 2002;287: 2958-2967.
19. Ratjen F,Walter H, Haug M, Meisner C, Grasemann H, Doring G. Diagnostic value of serum antibodies in early Pseudomonas aeruginosa infection in cystic fibrosis patients. Pediatr Pulmonol 2007;42:249-255.
20. Sachse F, von Eiff C, Becker K, Rudack C. Anti-inflammatory effects of ciprofloxacin in S. aureus Newman induced nasal inflammation in vitro. J Inflamm 2008;5:11. 10.1186/1476-9255-5-11.
21. Ziegeler S, Raddatz A, Hoff G, Buchinger H, Bauer I, Stockhausen A, Sasse H, Sandmann I, Hörsch S, Rensing H. Antibiotics modulate the stimulated cytokine response to endotoxin in a human ex vivo, in vitro model. Acta Anaesthesiol Scand 2006;50:1103-1110.
22. Davis SD, Fordham LA, Brody A, Noah TL, Retsch-Bogart GZ, Qaqish BF, Yankaskas BC, Johnson RC, Leigh MW. HRCT abnormalities reflect BALF inflammation and track changes in early CF. Am J Resp Crit Care Med 2007;175:943-950.
23. Ren CL, Morgan WJ, Konstan MW, Schechter MS, Wagener JS, Fisher KA, Regelmann WE. The Investigators and Coordinators of the Epidemiologic Study of Cystic Fibrosis. Presence of methicillin resistant Staphylococcus aureus in respiratory cultures from cystic fibrosis patients is associated with lower lung function. Pediatr Pulmonol 2007;42:513-518.
24. Dasenbrook EC, Merlo CA, Diener-West M, Lechtzin N, Boyle MP. Persistent methicillin-resistant Staphylococcus aureus and rate of FEV1 decline in cystic fibrosis. Am J Resp Crit Care Med 2008;178:814-821.
25. Noah TL, Black HR, Cheng P-W, Wood RE, Leigh MW. Nasal and bronchoalveolar lavage fluid cytokines in early cystic fibrosis. J Infect Dis 1997;175:638-647.
26. Bayat S, Louchani K, Verdiere B, Anglade D, Rahoui A, Sorin PM, Tod M, Petitjean O, Fraisse F, Grimbert FA. Comparison of 99mTc-DTPA and urea for measuring cefepime concentrations in epithelial lining fluid. Eur Respir J 2004;24:150-156.
27. Hankinson JL, Odencrantz JR, Fedan KB. Spirometric reference values from a sample of the general U.S. population. Am J Resp Crit Care Med 1999;159:179-187.